Cargando…
Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response
Hepatocellular carcinoma (HCC) can de novo develop in patients with chronic hepatitis C even after the achievement of sustained virologic response (SVR). We characterized de novo HCC after SVR, comparing it with HCC that developed in patients during persistent hepatitis C virus (HCV) infection. Char...
Autores principales: | Toyoda, Hidenori, Hiraoka, Atsushi, Uojima, Haruki, Nozaki, Akito, Shimada, Noritomo, Takaguchi, Koichi, Abe, Hiroshi, Atsukawa, Masanori, Matsuura, Kentaro, Ishikawa, Toru, Mikami, Shigeru, Watanabe, Tsunamasa, Itobayashi, Ei, Tsuji, Kunihiko, Arai, Taeang, Yasuda, Satoshi, Chuma, Makoto, Senoh, Tomonori, Tsutsui, Akemi, Okubo, Tomomi, Ehira, Takuya, Kumada, Takashi, Tanaka, Junko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279467/ https://www.ncbi.nlm.nih.gov/pubmed/34278176 http://dx.doi.org/10.1002/hep4.1716 |
Ejemplares similares
-
Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan
por: Toyoda, Hidenori, et al.
Publicado: (2019) -
Mac‐2‐binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C
por: Kawata, Kazuhito, et al.
Publicado: (2022) -
Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study
por: Tada, Toshifumi, et al.
Publicado: (2020) -
Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2020) -
Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment
por: Chuma, Makoto, et al.
Publicado: (2022)